- $373.37m
- $265.57m
Rezolute rises as drug shows promise for rare low blood sugar disorders
U.S. RESEARCH ROUNDUP-Goldman Sachs, Lantheus Holdings, Wells Fargo
U.S. STOCKS ON THE MOVE-Walt Disney, Titan Mining, Costco Wholesale
U.S. STOCKS ON THE MOVE-Nordson, Walt Disney, Titan Mining
U.S. STOCKS ON THE MOVE-Roku, Ciena, Diamond Hill
NASDAQ RESUMED AT 09:37 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM
Rezolute plunges after rare disease drug fails to meet main goal in late-stage trial
NASDAQ RESUMED AT 07:50 AM
Brief: Rezolute Announces Phase 3 SunRIZE Study Results In Congenital Hyperinsulinism
Rezolute's rare disease drug fails to meet main goal in late-stage trial (updated)
Rezolute's rare disease drug fails main goal in late-stage trial
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Brief: Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rezolute fiscal Q1 net loss widens to $18.2 mln
Brief: Rezolute Q1 EPS USD -0.18
Brief: Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Alphabet, Crowdstrike, Nike
Rezolute Q4 net loss widens to $24.4 mln